(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Tehran synagogue damaged by missile strike according to Iranian media - 2Top Fascinating Organic products: Which One Might You Want to Attempt?
- 32024's Driving Clearing Robots: Master Suggestions and Surveys
- 4I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- 5Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Ancient mass grave discovered in water cistern during Tel Azekah excavations
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- Dental Embed Innovation: An Achievement in Helpful Dentistry
- Flu is rising rapidly, driven by a new variant. Here's what to know
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- The Following Huge Thing: 5 Progressive Tech New businesses
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- What's Your #1 Pizza Beating Mix?
- Governments take targeted action as fuel prices hit retail
